At AAIC, researchers touted phospho-tau species, especially p217 and p181. They tick up in CSF as an early response to amyloid accumulation.
At this year’s AAIC, no sooner had scientists reported that phospho-tau in the CSF might reflect early responses to amyloid, than they reported parallel data for phospho-tau in blood.
Protein levels track with cognitive function and can distinguish Alzheimer’s patients from controls.
New genes linked to early and late-onset AD offer up mechanistic insight, potential targets for treatment.
Negative findings for AVP-786 belie positive findings from a separate Phase 3 trial announced earlier this year.
Changes in the composition of the cerebrospinal fluid and synapses may reveal novel insights into AD pathology.
ApoE2 homozygotes have a dramatically lower risk of AD than even the previously known low-risk E2/3 heterozygotes. More study of this protective allele could reveal roots of resilience.
The DIAN Trials Unit is nearing the end of its first two secondary prevention trials. It has begun a cognitive run-in period for its next trial, of a tau-based drug, and for a primary prevention study in people as young as 18.
In patient-derived neurons, tau mutations scupper lysosomes and SORLA shunts APP through different types of endosomes.